Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice

Headache

Volumn 45, Issue 6, 2005, Pages 624-631

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Almotriptan; Efficacy; Migraine; Patient satisfaction; Postmarketing study; Tolerability

Indexed keywords

ALMOTRIPTAN; ANALGESIC AGENT; ERGOTAMINE DERIVATIVE; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL PRACTICE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GERMANY; HEART PALPITATION; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; NAUSEA; PATIENT SATISFACTION; PHOTOSENSITIVITY; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RECURRENCE; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 20444421186     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.05129.x     Document Type: Article

References (16)

1. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001;10:1831-1845.
2. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
3. Diener HC. The efficacy of almotriptan 12.5 mg in acute migraine patients who respond poorly to sumatriptan 50 mg. Headache. 2004;44:471.
4. Lipton RB, Stewart MF. Acute migraine therapy: do doctors understand what patients want from therapy? Headache. 1999;39(suppl 2):S20-S26.
5. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache. 2003;43:36-43.
6. Dahlöf CGH, Tfelt-Hansen P, Massiou H, Fazekas A. Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology. 2001;57:1811-1817.
7. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000;20:588-598.
8. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002;22:453-461.
9. Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol. 2001;58:944-950.
10. Pascual J, Falk RM, Docekal R, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol. 2001;45:206-213.
11. Mathew NT. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache. 2002;42:32-40.
12. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259-1287.
13. Dahlöf CGH, Dodick D, Dowson AJ. How does almotriptan compare with other triptans. A review of data from placebo-controlled clinical trials. Headache. 2001;42:99-113.
14. Colman SS, Brod MI, Krishnamurthy A, et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther. 2001;23:127-143.
15. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
16. Mann RD. Prescription-event monitoring-recent progress and future horizons. Br J Clin Pharmacol. 1998;46:195-201.